Boston Scientific Corp. (BSX) agreed to pay $30 million to settle a whistle-blower lawsuit alleging the company’s Guidant unit knowingly sold defective heart devices, U.S. officials said.
Guidant, which Boston Scientific bought in 2006 for $27.5 billion, was accused of hiding defects in its Prizm line of heart defibrillators from patients, doctors and the U.S. Food and Drug Administration, the U.S. Justice Department, which joined the suit, said today in statement.
Click here to read more.
